STAT+: Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?

Fate Therapeutics said Friday that an experimental, off-the-shelf immunotherapy made from so-called natural killer cells induced complete tumor responses in just over half of the patients with advanced lymphoma treated in an early-stage clinical trial.

The 56% complete response rate reported for the Fate cancer treatment, called FT516, is still preliminary — and assessed from just 11 patients — but it is similar to efficacy reported with other types of cell therapy. However, the durability of the response to FT516 remains an important, unanswered question.

Continue to STAT+ to read the full story…